Who Supplies Vildagliptin to India from BRAZIL

To import finished pharmaceutical formulations containing Vildagliptin into India, the Central Drugs Standard Control Organization (CDSCO) mandates that importers obtain an Import Registration and License as per the Drugs and Cosmetics Act and Rules. This requirement ensures that imported drugs meet India's quality, safety, and efficacy standards. The registration process involves submitting an application to CDSCO, providing detailed product information, and obtaining approval before importation. The timeline for import drug registration can vary, but it typically ranges from several weeks to a few months, depending on the completeness of the application and the regulatory review process. For formulations under HS Code 30049099, specific requirements include providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificates, and stability data demonstrating compliance with Indian Pharmacopoeia standards. Additionally, a No Objection Certificate (NOC) from the manufacturer may be required. It's crucial for importers to ensure that all documentation is accurate and complete to facilitate a smooth import process.

Imported finished pharmaceutical formulations containing Vildagliptin must undergo quality testing at CDSCO-approved laboratories to verify compliance with Indian standards. This includes batch-wise testing, where each batch is sampled and analyzed for quality, purity, and potency. A Certificate of Analysis (CoA) from the manufacturer, along with stability data demonstrating compliance with ICH Zone IV standards, is required. The stability data should cover the proposed shelf life of the product under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to ensure that the imported products meet the necessary quality standards before they are released into the Indian market.

In April 2025, the CDSCO introduced new regulations requiring import registration and licenses for all imported medicines, including finished pharmaceutical formulations containing Vildagliptin. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The regulations stipulate that drugs manufactured in Special Economic Zones (SEZs) for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution. For unapproved and approved new drugs manufactured in SEZs, compliance with the requirements specified under the New Drugs and Clinical Trials Rules 2019 and the Drugs Rules 1945 is mandatory. These changes have streamlined the import process and enhanced the safety and efficacy of imported pharmaceutical products.

India imports finished pharmaceutical formulations containing Vildagliptin to meet the growing demand for diabetes management therapies. The domestic production of Vildagliptin formulations may not fully satisfy the market needs, leading to reliance on imports for patented or branded formulations and specific dosage forms not available locally. The market size for Vildagliptin formulations in India is substantial, with a significant number of exporters supplying to various countries. This indicates a robust demand for such formulations within the Indian pharmaceutical market.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 in India includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The total landed duty percentage is approximately 17.10%. These duties are applicable to imports from all countries, including Brazil, and are subject to change based on government policies and trade agreements.

India sources finished pharmaceutical formulations containing Vildagliptin from Brazil due to the competitive advantages offered by Brazilian manufacturers. Brazilian suppliers may provide patented formulations, specialized dosage forms, and high-quality products that meet international standards. While other countries like China, Germany, and the United States also supply such formulations, Brazil's unique advantages, such as favorable trade relations and specific product offerings, make it a preferred source for Indian importers.

India imports finished pharmaceutical formulations containing Vildagliptin from Brazil due to strategic reasons such as access to patented formulations, specialized dosage forms, and technology-licensed products. Brazilian manufacturers may offer specific formulations that are not produced domestically, fulfilling market needs and providing Indian buyers with high-quality alternatives.

When compared to other origins like China, the European Union, and the United States, Brazil offers competitive pricing, quality products, and reliable regulatory compliance. Brazil's unique advantage lies in its ability to provide specialized formulations and maintain consistent product quality, making it a preferred source for Indian importers seeking diverse product offerings.

Indian importers face potential supply chain risks when sourcing finished pharmaceutical formulations containing Vildagliptin from Brazil, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. While there have been no significant shortages reported, it's essential for importers to monitor these risks and develop contingency plans to mitigate potential disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and ensure a steady supply of products.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to align with demand forecasts and avoid overstocking.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments, to ensure compliance with quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the appropriate application forms